drugset / Trial / NCT02533505

Phase IV O2 Consumption Study in COPD Patients.

NCT02533505

Phase 4 Completed 51 enrolled AstraZeneca
RandomizedCrossoverDouble-blindTreatment

Summary

A Phase IV study evaluating changes in oxygen consumption and cardiac function in Subjects with Chronic obstructive pulmonary disease (COPD) with resting hyperinflation after administration of Symbicort pMDI 160/4.5 μg.

Timeline

Start
2015-08-25
Primary completion
2016-08-12
Completion
2016-08-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Budesonide Small molecule 160 ug Inhaled
Comparator Formoterol Other / unclassified 4.5 ug Inhaled